The National Institute for Health and Care Excellence (NICE) publish guidelines on the diagnosis and management of myeloma
NICE products and resources are produced for the NHS, local authorities, care providers, charities, and anyone who has a responsibility for commissioning or providing public health and social care services in the UK (excluding Scotland).
Its guidance is produced by healthcare professionals, NHS staff, patients and carers, members of the academic world, and other members of the wider healthcare and public health community.
The new guidelines recommend the use of Serum Protein Electrophoresis (SPE) and serum free light chains (sFLC) in the diagnosis of Multiple Myeloma and monoclonal gammopathy of undetermined significance (MGUS). NICE has not recommended the use of the urine Bence-Jones protein test (uBJP) in diagnosis of myeloma or MGUS.
This brings us one step closer to getting Freelite implemented as one of the main tools for the diagnosis of Multiple Myeloma.
The guidance is expected to be taken into full consideration by health and social care professionals and organisations when making decisions with the person receiving care.
You can see the guidelines here.